Dataset opportunity
Vesalio — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Vesalio, usable for Diagnostic AI and Computer Vision.
Score
68.1
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging Market = $1.8B in 2025, CAGR 35.1%.
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-13
FDA clears Vesalio’s latest mechanical thrombectomy device
medicaldevice-network.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Vesalio holds a unique and valuable Medical Imaging Dataset derived from its R&D and clinical trial operations in stroke treatment. The collection consists of proprietary angiographic imaging data, CT scans, and associated de-identified medical_records, providing a rich foundation for training and validating high-efficacy Diagnostic AI models for neurovascular conditions.
The global AI in Medical Imaging market was valued at USD 1.8 billion in 2025 and is projected to explode to USD 20.2 billion by 2033, demonstrating a massive 35.1% CAGR. [1] While this data involves sensitive patient information (PHI) and is subject to strict regulatory oversight, its rarity and direct relevance to the neurology segment—which is the largest application area in the market—make it an exceptionally valuable asset for AI developers seeking a competitive edge in a high-growth sector. [1] ⚠ Diligence (valuable data, access to negotiate): Clinical trial data involves sensitive patient health information (PHI) requiring de-identification; Proprietary angiographic imaging data is highly regulated; Data is primarily generated through R&D and regulatory approval processes · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence proves Vesalio holds a rare, proprietary dataset detailing the end-to-end treatment of stroke patients with its NeVa stent retriever. The data combines clinical trial records with corresponding pre- and post-procedure medical imaging, creating a uniquely valuable asset for diagnostic AI developers. In a global AI in Medical Imaging market growing at over 35% annually, this dataset offers a critical advantage for training and validating algorithms that predict treatment outcomes and optimize mechanical thrombectomy procedures.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
AI buyer demand is exceptionally high, driven by the AI in Medical Imaging market's aggressive expansion at a 35.1% CAGR and the critical need for specialized data to train diagnostic tools. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 1 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — Vesalio is an ideal target as it's a medical device SME whose core business is manufacturing and selling thrombectomy devices, with the resulting clinical and imaging data being a valuable, unmonetized by-product of its operations.
- Deep Qualification80
✓ pass — Vesalio is a medical device company whose R&D and clinical trials for its thrombectomy products generate a valuable, coherent medical imaging dataset; however, the specific rights to license this sensitive data are unclear from public documents.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence confirms structured clinical trial data from the VITAL and CLEAR studies, which is essential for training AI models to predict the efficacy of stroke interventions.
Image collection
The holder possesses curated pre- and post-procedure imaging datasets used to validate device performance, providing ideal ground-truth data for developing computer vision algorithms for stroke treatment assessment.
Industrial data
This evidence points to unique time-series data on the real-world and benchtop device performance of mechanical thrombectomy tools, enabling the development of predictive maintenance or performance optimization models.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Vesalio Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging Market = $1.8B in 2025, CAGR 35.1% (source: Grand View Research). Investment score 68.1/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Starseq — Medical Imaging Dataset Opportunity
View opportunity →healthcareIcentia — Medical Imaging Dataset Opportunity
View opportunity →healthcareEumediq — Medical Imaging Dataset Opportunity
View opportunity →